Moxonidine Chemical Properties

Melting point:

217-219° (dec)

Boiling point:

364.7±52.0 °C(Predicted)

Density 

1.52±0.1 g/cm3(Predicted)

storage temp. 

2-8°C

solubility 

Very slightly soluble in water, sparingly soluble in methanol, slightly soluble in methylene chloride, very slightly soluble in acetonitrile.

pka

7.11±0.10(Predicted)

color 

White to Almost white

Water Solubility 

800.3mg/L(temperature not stated)

Merck 

14,6293

InChIKey

WPNJAUFVNXKLIM-UHFFFAOYSA-N

CAS DataBase Reference

75438-57-2(CAS DataBase Reference)

Safety Information

RIDADR 

UN 2811 6.1/PG III

WGK Germany 

3

RTECS 

UV6260290

HS Code 

2933.99.5300

HazardClass 

6.1

PackingGroup 

III

MSDS

• Language:English Provider:Moxonidine
• Language:English Provider:SigmaAldrich

Moxonidine Usage And Synthesis

Description

Moxonidine, also known as Physiotens, is a highly selective imidazoline receptor agonist-Ⅰ by excitement ventrolateral medulla nucleus (RVLM)-Ⅰ type imidazoline receptor in the peripheral sympathetic nerve activity decreased. This receptor subtype is found in both the rostral ventro-lateral pressor and ventromedial depressor areas of the medulla oblongata.
Moxonidine therefore causes a decrease in sympathetic nervous system activity and, therefore, a decrease in blood pressure.
It is a new type of antihypertensive drug, commonly used in the treatment of essential hypertension. Compared to the older central-acting antihypertensives, moxonidine binds with much greater affinity to the imidazoline I1-receptor than to the α2-receptor. In contrast, clonidine binds to both receptors with equal affinity.
It may have a role when thiazides, beta-blockers, ACE inhibitors and calcium channel blockers are not appropriate or have failed to control blood pressure.

Physical and Chemical Properties

ensity: 1.52g/cm3, boiling point:  364.7 °C at 760 mmHg, flash point: 174.3 °C, crystallization, melting point: 217-219 degrees Celsius.

Application

• By stimulating the central presynaptic alpha 2-receptor and onset, and its antihypertensive effect of ACE inhibitors, calcium antagonists nifedipine and captopril similar. Treatment of essential hypertension.
• The intervention of renal interstitial fibrosis can protect the kidney.

Preparation

5-amino-4,6-dichloro-2-methyl pyrimidine and 1-acetyl-2-imidazolin-2-one. The product, reacting with sodium methanol can produce moxonidine.

Precautions

• There may be dry mouth, fatigue and headache at the beginning of treatment, occasional dizziness, insomnia, and weakness in the legs and so on.
• Sick sinus syndrome, the sinus node and atrioventricular Ⅱ-Ⅲ degree block, resting bradycardia (50 beats/min), unstable angina, severe liver disease, progressive renal dysfunction, angioedema patients should not use it.

References

https://en.wikipedia.org/wiki/Moxonidine

Description

Moxonidine, which is structurally related to clonidine, is a new centrally acting antihypertensive that acts as a stronger agonist at imidazole receptors and a weaker agonist at α2-adrenergic receptors than clonidine. It is also reported to have less side effects and a much reduced potential to produce a rebound in blood pressure on withdrawal. Clinically, moxonidine appears to have comparable antihypertensive efficacy with the ACE inhibitors and calcium antagonists.

Chemical Properties

White Solid

Originator

Beiersdorf (Germany)

Uses

Antihypertensive;Imidazoline receptor agonist

Uses

Moxonidine is an antihypertensive agent.

Definition

ChEBI: Moxonidine is an organohalogen compound and a member of pyrimidines.

brand name

Cynt (Lilly); Nucynt (Lilly); Norcynt (Lilly);Physiotens.

Biological Activity

Mixed I 1 imidazoline receptor and α 2 -adrenergic agonist; displays 40-fold higher affinity for I 1 receptors versus α 2 -adrenoceptors. Centrally acting antihypertensive agent.

Clinical Use

Antihypertensive agent (centrally acting agonist at I1 receptor, imidazoline and alpha2 adrenoceptors)

Metabolism

10-20% metabolised, predominantly to 4,5-dehydromoxonidine and to an aminomethanamidine derivative both of which are much less active than moxonidine. Moxonidine and its metabolites are almost entirely eliminated via the kidney. More than 90% of the dose is eliminated in the first 24 hours via the kidney, while approximately 1% is eliminated in the faeces

Moxonidine(75438-57-2)Related Product Information

• (Trifluoromethoxy)benzene
• 1-Methylimidazole
• MOXONIDINE HYDROCHLORIDE,MOXONIDINE HCL
• 5-METHYLCYTOSINE
• Pirimiphos-methyl
• Mestinon
• Bendazac L-lysine
• Losartan potassium
• Fursultiamine
• Terazosin
• Lovastatin
• 4-chloro-6-methoxy-2-methyl-N-(4,4,5,5-tetradeuterio-1H-imidazol-2-yl)pyrimidin-5-amine
• 5-Amino-4,6-dichloro-2-methylpyrimidine
• 4-chloro-6-methoxy-2-methylpyrimidin-5-amine
• 4-Chloro-6-methoxypyrimidine
• Imidazole
• Pyrimidine
• 6-Chloropyrimidin-4(3H)-one